Application of surface-enhanced raman spectroscopy for detection of beta amyloid using nanoshells

Plasmonics

Volumn 2, Issue 2, 2007, Pages 55-64

  Beier, Hope T ^a   Cowan, Christopher B ^b   Chou, I Hsien ^a   Pallikal, James ^b   Henry, James E ^b,d   Benford, Melodie E ^a   Jackson, Joseph B ^c   Good, Theresa A ^b   Coté, Gerard L ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b University of Marylandw Baltimore County   (United States)

^c Nanospectra Biosciences Inc   (United States)

^d LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

amyloid; Alzheimer's disease; Congo red; Nanoshells; Raman spectroscopy; Self assembled monolayer; SERS; Surface enhanced Raman spectroscopy

Indexed keywords

EID: 34547251133     PISSN: 15571955     EISSN: 15571963     Source Type: Journal    
DOI: 10.1007/s11468-007-9027-x     Document Type: Article

References (61)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang YQ, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366(9503):2112-2117
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population-prevalence estimates using the 2000 census. Arch Neurol 60(8):1119-1122
3. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356
4. Minino AM, Heron MP, Smith BL (2006) Deaths: preliminary data for 2004. Natl Vital Stat Rep 54(19): 1-50
5. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81(2):741-766
6. Ernst RL, Hay JW (1994) The U.S. economic and social costs of Alzheimer's disease revisited, Am J Public Health 84(8):1261-1264
7. Ariga T, Kobayashi K, Hasegawa A, Kiso M, Ishida H, Miyatake T (2001) Characterization of high-affinity binding between gangliosides and amyloid beta-protein. Arch Biochem Biophys 388(2):225-230
8. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang JP, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6(8):916-919
9. Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Perego C, De Luigi A, Vergani C, De Simoni MG (2004) Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Neurosci 24(17):4181-4186
10. Blanchard BJ, Chen A, Rozeboom LM, Stafford KA, Weigele P, Ingram VM (2004) Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc Natl Acad Sci USA 101(40):14326-14332
11. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98(15):8850-8855
12. Etcheberrigaray R, Tan M, Dewachter I, Kuiperi C, Van der Auwera I, Wera S, Qiao LX, Bank B, Nelson TJ, Kozikowski AP, Van Leuven F, Alkon DL (2004) Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci USA 101(30):11141-11146
13. Gelinas DS, DaSilva K, Fenili D, George-Hyslop PS, McLaurin J (2004) Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci USA 101:14657-14662
14. Ghanta J, Shen CL, Kiessling LL, Murphy RM (1996) A strategy for designing inhibitors of beta-amyloid toxicity. J Biol Chem 271 (47):29525-29528
15. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJF, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (4):547-554
16. Mandavilli A (2006) The amyloid code. Nat Med 12(7):747-751
17. Mount C, Downton C (2006) Alzheimer disease: progress or profit? Nat Med 12(7):780-784
18. Patel D, Henry J, Good T (2006) Attenuation of beta-amyloid induced toxicity by sialic acid-conjugated dendrimeric polymers. Biochim Biophys Acta 1760(12):1802-1809
19. Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88(9):1337-1342
20. Davis PC, Gray L, Albert M, Wilkinson W, Hughes J, Heyman A, Gado M, Kumar AJ, Destian S, Lee C, Duvall E, Kido D, Nelson MJ, Bello J, Weathers S, Jolesz F, Kikinis R, Brooks M (1992) The consortium to establish a registry for Alzheimers-disease (Cerad) .3. Reliability of a standardized Mri evaluation of Alzheimers-disease. Neurology 42(9):1676-1680
21. Duara R, Grady C, Haxby J, Sundaram M, Cutler NR, Heston L, Moore A, Schlageter N, Larson S, Rapoport SI (1986) Positron emission tomography in Alzheimers-disease. Neurology 36 (7):879-887
22. Haxby JV, Grady CL, Duara R, Schlageter N, Berg G, Rapoport SI (1986) Neocortical metabolic abnormalities precede non-memory cognitive defects in early Alzheimers-type dementia. Arch Neurol 43(9):882-885
23. Blennow K (2004) CSF biomarkers for mild cognitive impairment. J Intern Med 256:224-234
24. Mattson MP, Mark RJ, Furukawa K, Bruce AJ (1997) Disruption of brain cell ion homeostasis in Alzheimer's disease by oxy radicals, and signaling pathways that protect therefrom. Chem Res Toxicol 10(5):507-517
25. Rapport M, Dawson HN, Binder LI, Vitek MP, Ferreira A (2002) Tau is essential to β-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 99:6364-6369
26. Small GW (2002) Brain-imaging surrogate markers for detection and prevention of age-related memory loss. J Mol Neurosci 19(1-2):17-21
27. Varadarajan S, Yatin S, Aksenova M, Butterfield DA (2000) Review: Alzheimer's amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 130:184-208
28. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ (2002) Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 30:552-557
29. Wang SSS, Rymer DL, Good TA (2001) Reduction in cholesterol and sialic acid content protects cells from the toxic effects of beta-amyloid peptides. J Biol Chem 276(45):42027-42034
30. Zetterberg H, Wahnlund L-O, Blennow K (2003) Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 352:67-69
31. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-protein specifically disrupt cognitive function. Nat Neurosci 8(1):79-84
32. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL (2003) Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100 (18):10417-10422
33. Hardy J, Selkoe DJ (2002) Medicine - the amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580):353-356
34. Lee S, Fernandez EJ, Good TA (2007) Role of aggregation conditions in structure, stability, and toxicity of intermediates in the Aβ fibril formation pathway. Protein Sci 16(4):723-732
35. Lorenzo A, Yankner BA (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 91(25):12243-12247
36. Selkoe DJ, Schenk D (2003) Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43:545-584
37. Haes AJ, Chang L, Klein WL, Van Duyne RP (2005) Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc 127(7):2264-2271
38. Haes AJ, Hall WP, Chang L, Klein WL, Van Duyne RP (2004) A localized surface plasmon resonance biosensor: first steps toward an assay for Alzheimer's disease. Nano Lett 4(6):1029-1034
39. Georganopoulou DO, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 102(7):2273-2276
40. Kneipp K, Wang Y, Kneipp H, Perelman LT, Itzkan I, Dasari R, Feld MS (1997) Single molecule detection using surface-enhanced Raman scattering (SERS). Phys Rev Lett 78(9):1667-1670
41. Kneipp K, Wang Y, Kneipp H, Itzkan I, Dasari RR, Feld MS (1996) Population pumping of excited vibrational states by spontaneous surface-enhanced Raman scattering. Phys Rev Lett 76(14):2444-2447
42. Nie S M, Emery SR (1997) Probing single molecules and single nanoparticles by surface-enhanced Raman scattering. Science 275 (5303):1102-1106
43. Fleischmann M, Hendra PJ, McQuillan AJ (1973) Raman-spectra from electrode surfaces. J Chem Soc Chem Commun (3):80-81
44. Jeanmaire DL, Vanduyne RP (1977) Surface raman spectroelectrochemistry. 1. Heterocyclic, aromatic, and aliphatic-amines adsorbed on anodized silver electrode. J Electroanal Chem 84 (1):1-20
45. Baker GA, Moore DS (2005) Progress in plasmonic engineering of surface-enhanced Raman-scattering substrates toward ultratrace analysis. Anal Bioanal Chem 382(8):1751-1770
46. Kneipp K, Kneipp H, Itzkan I, Dasari RR, Feld MS (2002) Surface-enhanced Raman scattering and biophysics. J Phys Condens Matter 14(18):R597-R624
47. Oldenburg SJ, Jackson JB, Westcott SL, Halas NJ (1999) Infrared extinction properties of gold nanoshells. Appl Phys Lett 75 (19):2897-2899
48. Jackson JB, Halas NJ (2003) Controlling the surface enhanced Raman effect on nanoshells in a film geometry. Abstr Pap Am Chem Soc 225:U447
49. Jackson JB, Halas NJ (2004) Surface-enhanced Raman scattering on tunable plasmonic nanoparticle substrates. Proc Natl Acad Sci USA 101(52):17930-17935
50. Oldenburg SJ, Westcott SL, Averitt RD, Halas NJ (1999) Surface enhanced Raman scattering in the near infrared using metal nanoshell substrates. J Chem Phys 111(10):4729-4735
51. Zhu ZH, Zhu T, Liu ZF (2004) Raman scattering enhancement contributed from individual gold nanoparticles and interparticle coupling. Nanotechnology 15(3):357-364
52. Li KR, Stockman MI, Bergman DJ (2003) Self-similar chain of metal nanospheres as an efficient nanolens. Phys Rev Lett 91(22)
53. ChooSmith LP, GarzonRodriguez W, Glabe CG, Surewicz WK (1997) Acceleration of amyloid fibril formation by specific binding of A beta-(1-40) peptide to ganglioside-containing membrane vesicles. J Biol Chem 272(37):22987-22990
54. Kakio A, Nishimoto S, Yanagisawa K, Kozutsumi Y, Matsuzaki K (2001) Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem 276(27):24985-24990
55. Kakio A, Yano Y, Takai D, Kuroda Y, Matsumoto O, Kozutsumi Y, Matsuzaki K (2004) Interaction between amyloid beta-protein aggregates and membranes. J Pept Sci 10(10):612-621
56. Matsuzaki K, Horikiri C (1999) Interactions of amyloid beta-peptide (1-40) with ganglioside-containing membranes. Biochemistry 38(13):4137-4142
57. Wakabayashi M, Okada T, Kozutsumi Y, Matsuzaki K (2005) GM1 ganglioside-mediated accumulation of amyloid beta-protein on cell membranes. Biochem Biophys Res Commun 328(4):1019-1023
58. Williamson MP, Suzuki Y, Bourne NT, Asakura T (2006) Binding of amyloid beta-peptide to ganglioside micelles is dependent on histidine-13. Biochem J 397:483-490
59. Iconomidou VA, Chryssikos GD, Gionis V, Hoenger A, Hamodrakas SJ (2003) FT-Raman spectroscopy as diagnostic tool of Congo red binding to amyloids. Biopolymers 72(3):185-192
60. Miura T, Yamamiya C, Sasaki M, Suzuki K, Takeuchi H (2002) Binding mode of Congo red to Alzheimer's amyloid beta-peptide studied by UV Raman spectroscopy, J Raman Spectrosc 33(7):530-535
61. Khurana R, Uversky VN, Nielsen L, Fink AL (2001) Is Congo red an amyloid-specific dye? J Biol Chem 276(25):22715-22721